ORYZON GENOMICS news, videos and press releases
For more news please use our advanced search feature.
ORYZON GENOMICS - More news...
ORYZON GENOMICS - More news...
- ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
- ORYZON to Provide Corporate Progress Updates at Several Events in April
- ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023
- ORYZON to Provide Corporate Progress Updates at Several Events in February-March
- ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024
- ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)
- ORYZON to Provide Corporate Progress Updates at Several Events in January
-
Executive interview with Carlos Buesa, CEO of Oryzon Genomics
- ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.
- ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million
- ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)
- ORYZON to Provide Corporate Progress Updates at Several Events in November
- ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023
- ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder
- ORYZON Receives Two Grants to Further Explore the Role of Epigenetic Targets in the Treatment of Neuronal Pathologies
- ORYZON to Provide Corporate Progress Updates at Several Events in October
- ORYZON to Give Updates on Corporate Progress in September
- Oryzon Announces Completed Patient Recruitment in the PORTICO Phase IIb Trial of vafidemstat in Borderline Personality Disorder
- ORYZON Reports Financial Results and Corporate Updates for Half-Year Ending June 30, 2023
- Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder
- ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders
- Positive Preclinical Data of ORY-4001 for the Treatment of Charcot-Marie-Tooth (CMT) Disease Presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting
- ORYZON to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease at the 2023 Peripheral Nerve Society (PNS) Annual Meeting
- ORYZON to Present Trial in Progress Phase Ib FRIDA Study at the Upcoming 2023 ASCO Annual Meeting
- ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2023
- ORYZON to Give Updates on Corporate Progress in May-June
- ORYZON Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder
- ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat in Relapsed/Refractory FLT3-mutant Acute Myeloid Leukemia Patients
- ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders
- ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology
